Overcoming a Big Barrier: Hesperos CEO awarded for Blood-Brain Barrier Innovation
Getting drugs past the neuroprotective blood-brain barrier (BBB) has been a perplexing problem and formidable challenge for researchers and pharmaceutical companies alike. Hesperos’s creation of a microfluidic model capable of mimicking in vivo characteristics of the blood-brain barrier for prolonged periods was therefore widely welcomed, and recently earned CEO Michael L. Shuler recognition from the American … Read more